AstraZeneca

COMBACTE-MAGNET launched to revitalize antibiotic development

Wednesday, February 4, 2015 01:41 PM

Thirty-three European academic partners and five pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the Innovative Medicines Initiative (IMI) antimicrobial resistance research program New Drugs 4 Bad Bugs (ND4BB).

More... »

Quest Diagnostics

AstraZeneca, MD Anderson collaborate for ovarian/gynecologic cancers

Monday, February 2, 2015 01:50 PM

AstraZeneca and the University of Texas MD Anderson Cancer Center have announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

More... »


AstraZeneca collaborates to use CRISPR technology

Friday, January 30, 2015 12:27 PM

AstraZeneca has announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The four research collaborations are with the Wellcome Trust Sanger Institute, Cambridge, U.K.; the Innovative Genomics Initiative, California; Thermo Fisher Scientific, Waltham, Mass.; and the Broad Institute/Whitehead Institute, Cambridge, Mass. The technology will allow AZ to identify and validate new drug targets in preclinical models that closely resemble human disease.

More... »

Astellas Pharma hires global executive Eric Terhaerdt

Friday, January 16, 2015 10:11 AM

Eric Terhaerdt has been named senior vice president of Global Development Operations for Astellas Pharma, based in Tokyo, Japan. Terhaerdt will be located at Astellas' headquarters for the Americas in Northbrook, Ill., and will report to Dr. Bernie Zeiher, executive vice president, Global Development and Therapeutic Area head: immunology, infectious disease, transplantation and central nervous system and pain, with Astellas Pharma Global Development.

More... »

Moderna, Merck to develop messenger RNA-based antiviral vaccines

Wednesday, January 14, 2015 12:41 PM

Moderna Therapeutics has announced a license and collaboration agreement with Merck, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna’s work in the collaboration will be led by Valera, its venture focused on the development of mRNA vaccines and therapeutics to fight infectious disease. Moderna is privately held, Cambridge, Mass.-based company founded by Flagship VentureLabs.

More... »

Tetragenetics, MedImmune collaborate on ion channel drug discovery program

Thursday, January 8, 2015 01:03 PM

Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune's antibody drug discovery programs.

More... »

As GSK restructuring cuts 900 jobs in RTP, Parexel absorbs 450 of them in new business unit

Monday, December 8, 2014 01:30 PM

GlaxoSmithKline’s global restructuring was felt sharply in North Carolina this week as it announced plans to cut 900 jobs in Research Triangle Park (RTP), where it has 2,500 employees and contractors working in research and development.

More... »

Cancer Research U.K., AstraZeneca to collaborate

Monday, December 1, 2014 12:48 PM

AstraZeneca and Cancer Research U.K. have signed a memorandum of understanding through which Cancer Research U.K. drug discovery investigators would be given access to state-of-the-art drug discovery facilities at the new AZ MRC U.K. Center for Lead Discovery to be built in Cambridge.

More... »

AstraZeneca to expand its Maryland biologics manufacturing center, add 300 jobs

Monday, November 24, 2014 02:44 PM

AstraZeneca plans to expand its biologics manufacturing center in Frederick, Md. The more than $200 million project will increase production capacity at the facility to support AZ’s maturing pipeline, and will help the company keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AZ’s overall pipeline.

More... »

AstraZeneca, Manchester University form Advanced Drug Delivery Center

Thursday, November 6, 2014 12:31 PM

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients. Together, they are launching the North West Center for Advanced Drug Delivery, which will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the university.

More... »


CWWeekly

April 20

Christie Clinic, PMG Research's 12th clinical research site, expands its geographic reach north to Illinois

Clinipace acquires Accovion to expand European presence, following an infusion of equity that could lead to more deals

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs